FluMist Quadrivalent
STN: 125020
Proper Name: Influenza Vaccine
Tradename: FluMist Quadrivalent
Manufacturer: MedImmune, LLC
Indications:
- For active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FluMist Quadrivalent is approved for use in persons 2 through 49 years of age
Product Information
Supporting Documents
- June 30, 2023 Approval Letter - FluMist Quadrivalent
- January 12, 2023 Approval Letter - FluMist
- July 27, 2022 Approval Letter - FluMist Quadrivalent
- July 20, 2021 Approval Letter - FluMist
- July 9, 2020 Approval Letter - FluMist
- April 14, 2020 Approval Letter - FluMist
- July 15, 2019 Approval Letter - FluMist
- February 28, 2019 Approval Letter - FluMist Quadrivalent
To remove information from the Use in Specific Populations section of the Highlights of Prescribing Information of the package insert (PI) for clarity. - August 10, 2018 Approval Letter - FluMist Quadrivalent
To include the 2018-2019 United States formulation and associated labeling revisions. - May 15, 2018 Approval Letter - FluMist Quadrivalent
To revise package insert to comply with Pregnancy and Lactation Labeling Rule. - March 17, 2017 Approval Letter - FluMist Quadrivalent
To revise the Ovalbumin test release specification and make the associated changes to the labeling. - Supporting Documents older than three years - FluMist Quadrivalent
Related Information
- FDA Information Regarding FluMist Quadrivalent Vaccine
- Questions and Answers - FluMist Quadrivalent (Influenza Virus Vaccine Live, Intranasal)
- FluMist